Taken together, these results demonstrate that USP1 promote B-ALL progression at least partially via the ID1/AKT signaling pathway, and USP1 inhibitors might be promising therapeutic application for B-ALL. This evidence concerns the gene ID1 and precursor B-cell acute lymphoblastic leukemia.